TAK in the 13F filings
Takeda Pharmaceutical Co Ltd · CUSIP 874060205
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 16
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 2 listed it in both
- Shares listed
- 33,817,640
- combined, among listed positions
- Reported value
- $527m
- combined, at the quarter end
Among the 92 comparable managers: 11 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +4,956,524.
Managers listing TAK in Q4 2025
16 of 16 holders
Largest increases and reductions, by shares
Increases
- D. E. Shaw & Co.existing position · 4,293,750 shares now+4,012,456
- Arrowstreet Capital LPexisting position · 5,682,847 shares now+2,854,069
- Voloridge Investment Management LLCexisting position · 962,502 shares now+880,289
- Citadel Advisors LLCexisting position · 389,734 shares now+314,110
- Balyasny Asset Management LLCnew position · 141,024 shares now+141,024
Reductions
- Millennium Management LLCexisting position · 890,089 shares now-1,666,117
- Renaissance Technologies LLCexisting position · 2,618,300 shares now-1,246,300
- Walleye Capital LLCexisting position · 83,083 shares now-138,439
- Fidelity (FMR LLC)existing position · 4,056,868 shares now-130,078
- AQR Capital Management LLCexisting position · 679,277 shares now-87,007
New positions and exits
New (4)
Exited (3)
- Squarepoint Ops LLCwas $3.0m
- Jane Street Group LLCwas $1.6m
- Marshall Wace LLPwas $406k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2018 | 3 | $83m | n.a. | n.a. |
| Q1 2019 | 12 | $1.2bn | n.a. | n.a. |
| Q2 2019 | 6 | $721m | n.a. | n.a. |
| Q3 2019 | 9 | $718m | n.a. | n.a. |
| Q4 2019 | 6 | $645m | n.a. | n.a. |
| Q1 2020 | 4 | $362m | n.a. | n.a. |
| Q2 2020 | 4 | $395m | n.a. | n.a. |
| Q3 2020 | 4 | $423m | n.a. | n.a. |
| Q4 2020 | 5 | $549m | n.a. | n.a. |
| Q1 2021 | 4 | $699m | n.a. | n.a. |
| Q2 2021 | 4 | $476m | n.a. | n.a. |
| Q3 2021 | 4 | $410m | n.a. | n.a. |
| Q4 2021 | 2 | $111m | n.a. | n.a. |
| Q2 2022 | 3 | $69m | n.a. | n.a. |
| Q3 2022 | 3 | $68m | n.a. | n.a. |
| Q4 2022 | 5 | $208m | n.a. | n.a. |
| Q1 2023 | 5 | $349m | n.a. | n.a. |
| Q2 2023 | 5 | $353m | n.a. | n.a. |
| Q3 2023 | 4 | $311m | n.a. | n.a. |
| Q4 2023 | 5 | $374m | 4 | 1 |
| Q1 2024 | 3 | $228m | 0 | 2 |
| Q2 2024 | 4 | $243m | 3 | 1 |
| Q3 2024 | 3 | $236m | 2 | 1 |
| Q4 2024 | 3 | $271m | 1 | 2 |
| Q1 2025 | 3 | $256m | 3 | 0 |
| Q2 2025 | 2 | $257m | 2 | 0 |
| Q3 2025 | 2 | $253m | 2 | 0 |
| Q4 2025 | 4 | $355m | 11 | 8 |
| Q1 2026 | 3 | $467m | 13 | 7 |
| Q2 2026 | 3 | $410m | 13 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TAK and LLY →TAK and JNJ →TAK and VRTX →Choose a stock to compare with TAK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TAK, latest filings →Back to the 13F Explorer →